Skip to main navigation Skip to search Skip to main content

Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Chimeric antigen receptor (CAR)-natural killer (NK)-cell therapy has emerged as a promising strategy in the treatment of haematological malignancies and solid cancers. Leveraging the innate immune properties of NK cells, CAR-NK-cell therapies offer potential advantages for cell therapy, including safety of use in the allogeneic setting and reduced risk of toxicity. This Nutshell provides an overview of the latest advancements in CAR-NK-cell therapy and the challenges that remain.

Original languageEnglish (US)
Pages (from-to)443-446
Number of pages4
JournalBritish Journal of Haematology
Volume206
Issue number2
DOIs
StatePublished - Feb 2025

Keywords

  • CAR-NK
  • immunotherapy
  • NK cells

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Advances and challenges in chimeric antigen receptor-natural killer cell immunotherapy for cancer'. Together they form a unique fingerprint.

Cite this